Laigo Bio raises €17M
Laigo Bio announced a Seed round of €17M on 28 March 2026. The company operates in HealthTech and is based in Netherlands. It was founded by Neill Moray Mackenzie, CEO.
Founder
Neill Moray Mackenzie
CEO, Laigo Bio
Outreach angles
- -Laigo Bio's SureTACs platform attracted an oversubscribed seed round, with Biovance Capital joining as co-lead alongside existing co-lead Kurma Partners - a rare dual co-lead structure signaling strong institutional conviction.
- -The Utrecht-based biotech closed a final tranche that exceeded its target, suggesting significant demand from investors beyond the initial cap.
- -SureTACs as a platform name implies a targeted cell therapy or biologics approach, positioning Laigo in one of biotech's most competitive and well-funded niches.
Signals
SeedDeep TechHealthcare
Round details
Company: Laigo Bio
Domain: laigobio.com
Amount: €17M
Stage: Seed
Industry: HealthTech
Country: Netherlands
Announced: 28 March 2026
Other HealthTech raises
Recently funded in Netherlands